The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease

Neuroscience

Volumn 198, Issue , 2011, Pages 221-231

  Surmeier, D J ^a   Guzman, J N ^a   Sanchez Padilla, J ^a   Schumacker, P T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcium; Endoplasmic reticulum; L type channels; Mitochondrial oxidant stress; Pacemaking; Parkinson's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALBINDIN; CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CAV1.2 CALCIUM CHANNEL; CAV1.3 CALCIUM CHANNEL; CREATINE; DIHYDROPYRIDINE DERIVATIVE; DJ 1 PROTEIN; DOPAMINE; ISRADIPINE; LEVODOPA; MITOCHONDRIAL DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELEGILINE; UBIDECARENONE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CALCIUM SIGNALING; CALCIUM TRANSPORT; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; HYPERTENSION; LOCUS CERULEUS; MITOCHONDRIAL GENOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; RESPIRATORY CHAIN; REVIEW; RISK REDUCTION; SOMATIC MUTATION; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; CALCIUM; CALCIUM CHANNELS, L-TYPE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; HUMANS; LEVODOPA; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 81255149611     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.045     Document Type: Review

References (120)

1. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006, 7:207-219.
2. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
3. Bandopadhyay R., de Belleroche J. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol Med 2010, 16:27-36.
4. Bardo S., Cavazzini M.G., Emptage N. The role of the endoplasmic reticulum Ca2+ store in the plasticity of central neurons. Trends Pharmacol Sci 2006, 27:78-84.
5. Beal M.F., Matthews R.T., Tieleman A., Shults C.W. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998, 783:109-114.
6. Bean B.P. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci U S A 1984, 81:6388-6392.
7. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008, 70:1438-1444.
8. Belzunegui S., San Sebastián W., Garrido-Gil P., Izal-Azcárate A., Vázquez-Claverie M., López B., Marcilla I., Lanciego J.L., Luquin M.R. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 2007, 61:1006-1012.
9. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38:515-517.
10. Berridge M.J. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 2002, 32:235-249.
11. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000, 1:11-21.
12. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., Greenamyre J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22:404-420.
13. Blythe S.N., Wokosin D., Atherton J.F., Bevan M.D. Cellular mechanisms underlying burst firing in substantia nigra dopamine neurons. J Neurosci 2009, 29:15531-15541.
14. Bonci A., Grillner P., Mercuri N.B., Bernardi G. L-type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J Neurosci 1998, 18:6693-6703.
15. Bouman L., Schlierf A., Lutz A.K., Shan J., Deinlein A., Kast J., Galehdar Z., Palmisano V., Patenge N., Berg D., Gasser T., Augustin R., Trümbach D., Irrcher I., Park D.S., Wurst W., Kilberg M.S., Tatzelt J., Winklhofer K.F. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 2011, 18:769-782.
16. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
17. Calne D.B., Langston J.W. Aetiology of Parkinson's disease. Lancet 1983, 2:1457-1459.
18. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., Surmeier D.J. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
19. Choi Y.M., Kim S.H., Chung S., Uhm D.Y., Park M.K. Regional interaction of endoplasmic reticulum Ca2+ signals between soma and dendrites through rapid luminal Ca2+ diffusion. J Neurosci 2006, 26:12127-12136.
20. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 2011, 12:359-366.
21. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek J.R., Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 2007, 26:56-65.
22. Csordás G., Renken C., Várnai P., Walter L., Weaver D., Buttle K.F., Balla T., Mannella C.A., Hajnóczky G. Structural and functional features and significance of the physical linkage between ER and mitochondria. J Cell Biol 2006, 174:915-921.
23. Cui G., Okamoto T., Morikawa H. Spontaneous opening of T-type Ca2+ channels contributes to the irregular firing of dopamine neurons in neonatal rats. J Neurosci 2004, 24:11079-11087.
24. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999, 122(Pt 8):1421-1436.
25. de Brito O.M., Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456:605-610.
26. de Lau L.M., Giesbergen P.C., de Rijk M.C., Hofman A., Koudstaal P.J., Breteler M.M. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004, 63:1240-1244.
27. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alperovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg, Psychiatry 1997, 62:10-15.
28. Deister C.A., Teagarden M.A., Wilson C.J., Paladini C.A. An intrinsic neuronal oscillator underlies dopaminergic neuron bursting. J Neurosci 2009, 29:15888-15897.
29. Del Tredici K., Braak H. Idiopathic Parkinson's disease: staging an alpha-synucleinopathy with a predictable pathoanatomy. Molecular mechanisms of Parkinson's disease 2004, 1-32. Landes Bioscience, Georgetown, TX. P.J. Kahle, C. Haas (Eds.).
30. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
31. Egawa N., Yamamoto K., Inoue H., Hikawa R., Nishi K., Mori K., Takahashi R. The endoplasmic reticulum stress sensor, ATF6alpha, protects against neurotoxin-induced dopaminergic neuronal death. J Biol Chem 2011, 286:7947-7957.
32. Eisenberg M.J., Brox A., Bestawros A.N. Calcium channel blockers: an update. Am J Med 2004, 116:35-43.
33. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 2007, 104:1325-1330.
34. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 2005, 252(Suppl 4):IV37-IV42. The Parkinson Study Group.
35. Fitton A., Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990, 40:31-74.
36. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 1992, 648:42-62.
37. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992, 32:667-676.
38. Gibb W.R., Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991, 54:388-396.
39. Gleichmann M., Mattson M.P. Neuronal calcium homeostasis and dysregulation. Antioxid Redox Signal 2011, 14:1261-1273.
40. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-2. Action potential generating mechanisms and morphological correlates. Neuroscience 1983, 10:317-331.
41. Greenamyre J.T., Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004, 304:1120-1122.
42. Gu M., Gash M.T., Cooper J.M., Wenning G.K., Daniel S.E., Quinn N.P., Marsden C.D., Schapira A.H. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997, 12:418-422.
43. Guo M. What have we learned from Drosophila models of Parkinson's disease?. Prog Brain Res 2010, 184:3-16.
44. Guzman J.N., Sánchez-Padilla J., Chan C.S., Surmeier D.J. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci 2009, 29:11011-11019.
45. Guzman J.N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P.T., Surmeier D.J. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
46. Hanson G.T., Aggeler R., Oglesbee D., Cannon M., Capaldi R.A., Tsien R.Y., Remington S.J. Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J Biol Chem 2004, 279:13044-13053.
47. Harman D. The biologic clock: the mitochondria?. J Am Geriatr Soc 1972, 20:145-147.
48. Hayashi T., Rizzuto R., Hajnoczky G., Su T.P. MAM: more than just a housekeeper. Trends Cell Biol 2009, 19:81-88.
49. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008, 4:600-609.
50. Hetz C.A. ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage. Antioxid Redox Signal 2007, 9:2345-2355.
51. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
52. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966, 18:925-964.
53. Huisman E., Uylings H.B., Hoogland P.V. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov Disord 2008, 23:1407-1413.
54. Ilijic E., Guzman J.N., Surmeier D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011, 43:364-371.
55. Ito H., Goto S., Sakamoto S., Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann Neurol 1992, 32:543-550.
56. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006, 26:5256-5264.
57. Khaliq Z.M., Bean B.P. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci 2010, 30:7401-7413.
58. Kirichok Y., Krapivinsky G., Clapham D.E. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004, 427:360-364.
59. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988, 318:876-880.
60. Klegeris A., McGeer E.G., McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 2007, 20:351-357.
61. Koschak A., Reimer D., Huber I., Grabner M., Glossmann H., Engel J., Striessnig J. Alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem 2001, 276:22100-22106.
62. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006, 38:518-520.
63. Kupsch A., Sautter J., Schwarz J., Riederer P., Gerlach M., Oertel W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996, 741:185-196.
64. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002, 3:862-872.
65. Magyar K., Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004, 25:233-242.
66. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994, 36:876-881.
67. Mannhold R., Rekker R.F., Sonntag C., ter Laak A.M., Dross K., Polymeropoulos E.E. Comparative evaluation of the predictive power of calculation procedures for molecular lipophilicity. J Pharm Sci 1995, 84:1410-1419.
68. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999, 157:142-149.
69. Matzuk M.M., Saper C.B. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985, 18:552-555.
70. McCann M.J., Rogers R.C. Oxytocin excites gastric-related neurones in rat dorsal vagal complex. J Physiol 1990, 428:95-108.
71. McCormack J.G., Halestrap A.P., Denton R.M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 1990, 70:391-425.
72. Mercuri N.B., Bonci A., Calabresi P., Stratta F., Stefani A., Bernardi G. Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br J Pharmacol 1994, 113:831-838.
73. Mogami H., Nakano K., Tepikin A.V., Petersen O.H. Ca2+ flow via tunnels in polarized cells: recharging of apical Ca2+ stores by focal Ca2+ entry through basal membrane patch. Cell 1997, 88:49-55.
74. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
75. Moore D.J., Zhang L., Troncoso J., Lee M.K., Hattori N., Mizuno Y., Dawson T.M., Dawson V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 2005, 14:71-84.
76. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
77. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010, 8. e1000298.
78. Nedergaard S., Flatman J.A., Engberg I. Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 1993, 466:727-747.
79. Nicholls D. Mitochondrial bioenergetics, aging, and aging-related disease. Sci Aging Knowl Environ 2002, 2002:e12.
80. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003, 4:552-565.
81. Park M.K., Choi Y.M., Kang Y.K., Petersen O.H. The endoplasmic reticulum as an integrator of multiple dendritic events. Neuroscientist 2008, 14:68-77.
82. Park M.K., Petersen O.H., Tepikin A.V. The endoplasmic reticulum as one continuous Ca(2+) pool: visualization of rapid Ca(2+) movements and equilibration. EMBO J 2000, 19:5729-5739.
83. Paschen W., Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium 2005, 38:409-415.
84. Pignatelli A., Ackman J.B., Vigetti D., Beltrami A.P., Zucchini S., Belluzzi O. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. Pflugers Arch 2009, 457:899-915.
85. Pignatelli A., Kobayashi K., Okano H., Belluzzi O. Functional properties of dopaminergic neurones in the mouse olfactory bulb. J Physiol 2005, 564:501-514.
86. Ping H.X., Shepard P.D. Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 1996, 7:809-814.
87. Postuma R.B., Lang A.E., Massicotte-Marquez J., Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
88. Przedborski S., Tieu K., Perier C., Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004, 36:375-379.
89. Puopolo M., Raviola E., Bean B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 2007, 27:645-656.
90. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38:277-301.
91. Ritz B., Rhodes S.L., Qian L., Schernhammer E., Olsen J.H., Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010, 67:600-606.
92. Rizzuto R., Pozzan T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 2006, 86:369-408.
93. Romo R., Schultz W. Dopamine neurons of the monkey midbrain: contingencies of responses to active touch during self-initiated arm movements. J Neurophysiol 1990, 63:592-606.
94. Rose C.R., Konnerth A. Stores not just for storage. Intracellular calcium release and synaptic plasticity. Neuron 2001, 31:519-522.
95. Ryu E.J., Harding H.P., Angelastro J.M., Vitolo O.V., Ron D., Greene L.A. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 2002, 22:10690-10698.
96. Saper C.B., Sorrentino D.M., German D.C., de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 1991, 29:577-584.
97. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008, 7:97-109.
98. Schapira A.H. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008, 15(Suppl 1):5-13.
99. Scholze A., Plant T.D., Dolphin A.C., Nürnberg B. Functional expression and characterization of a voltage-gated CaV1. 3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. Mol Endocrinol 2001, 15:1211-1221.
100. Schwyn R.C., Fox C.A. The primate substantia nigra: a Golgi and electron microscopic study. J Hirnforsch 1974, 15:95-126.
101. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., Troconso J.C., Dawson V.L., Dawson T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
102. Shults C.W., Haas R.H., Passov D., Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997, 42:261-264.
103. Sinnegger-Brauns M.J., Huber I.G., Koschak A., Wild C., Obermair G.J., Einzinger U., Hoda J.C., Sartori S.B., Striessnig J. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 2009, 75:407-414.
104. Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants as therapies. Discov Med 2011, 11:106-114.
105. Soong N.W., Hinton D.R., Cortopassi G., Arnheim N. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 1992, 2:318-323.
106. Stevens D.R., Haas H.L. Calcium-dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons. J Physiol 1996, 493(Pt 3):747-754.
107. Striessnig J., Koschak A., Sinnegger-Brauns M.J., Hetzenauer A., Nguyen N.K., Busquet P., Pelster G., Singewald N. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans 2006, 34:903-909.
108. Stutzmann G.E., Smith I., Caccamo A., Oddo S., Laferla F.M., Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 2006, 26:5180-5189.
109. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007, 30:244-250.
110. Taddese A., Bean B.P. Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 2002, 33:587-600.
111. Toescu E.C. Normal brain ageing: models and mechanisms. Philos Trans R Soc Lond B Biol Sci 2005, 360:2347-2354.
112. Travagli R.A., Gillis R.A., Rossiter C.D., Vicini S. Glutamate and GABA-mediated synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. Am J Physiol 1991, 260:G531-G536.
113. Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 2005, 85:201-279.
114. Vila M., Ramonet D., Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008, 107:317-328.
115. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005, 39:359-407.
116. Wang H.Q., Takahashi R. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid Redox Signal 2007, 9:553-561.
117. Williams J.T., North R.A., Shefner S.A., Nishi S., Egan T.M. Membrane properties of rat locus coeruleus neurones. Neuroscience 1984, 13:137-156.
118. Wilson C.J., Callaway J.C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 2000, 83:3084-3100.
119. Yamada T., McGeer P.L., Baimbridge K.G., McGeer E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990, 526:303-307.
120. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999, 154:1423-1429.